Important Clarification & Product Assessment (English):

The product name "DIAMPA L XR 25+5+1000mg Tablets" suggests a triple-combination antidiabetic medication. However, this specific formulation is not pharmacologically valid if interpreted as containing dapagliflozin, for the following reasons:

1. ✅ Linagliptin 5mg – Valid: This is the only approved dose of linagliptin worldwide.
2. ✅ Metformin XR 1000mg – Valid: A standard extended-release strength.
3. ❌ "25mg" as Dapagliflozin – Invalid: Dapagliflozin is only approved in 5mg and 10mg doses—25mg does not exist for dapagliflozin.

Most Likely Explanation:

Despite the brand name "DIAMPA" (typically associated with dapagliflozin in Pakistan), the "25" almost certainly refers to Empagliflozin 25mg—a different SGLT2 inhibitor that is approved at 25mg.

Therefore, DIAMPA L XR 25+5+1000mg is likely a misbranded or locally marketed product containing:

1. Empagliflozin 25mg (SGLT2 inhibitor)
2. Linagliptin 5mg (DPP-4 inhibitor)
3. Metformin Hydrochloride Extended-Release 1000mg

📌 Note: While "DIAMPA" is commonly used for dapagliflozin (e.g., by Sami Pharma), some local manufacturers may use similar names for empagliflozin-based combinations. Always verify the active ingredient on the packaging—not just the brand name.

Assumed Product Composition (Based on Clinical Plausibility):

Active Ingredients:

1. Empagliflozin 25mg
2. Linagliptin 5mg
3. Metformin XR 1000mg

This triple combination is pharmacologically sound and aligns with global treatment guidelines for type 2 diabetes.

Product Full Description (English):

Uses:

1. Triple therapy for adults with type 2 diabetes inadequately controlled on dual therapy
2. Patients requiring simplified once-daily regimen with cardio-renal protection
3. Those with established cardiovascular disease, heart failure, or chronic kidney disease

Key Benefits:

1. Empagliflozin: Reduces CV death, hospitalization for heart failure, and slows CKD progression
2. Linagliptin: Weight-neutral, low hypoglycemia risk, no renal dose adjustment
3. Metformin XR: Minimizes GI side effects vs. immediate-release
4. Once-daily dosing improves adherence

How to Use:

Take one tablet once daily with the evening meal. Swallow whole—do not crush or chew.

When Not to Use:

1. Type 1 diabetes or diabetic ketoacidosis
2. eGFR <30 mL/min
3. History of Fournier’s gangrene
4. Hypersensitivity to any component

Side Effects:

1. Common: Genital yeast infections, UTIs, increased urination
2. Serious: Lactic acidosis (metformin), Fournier’s gangrene (SGLT2i), pancreatitis (DPP-4i class)

Warnings:

1. Monitor renal function
2. Discontinue before surgery/contrast imaging
3. Counsel on symptoms of ketoacidosis and lactic acidosis

Critical Recommendation:

🔍 Check the blister pack or label for the exact active ingredients.

1. If it says "Empagliflozin", then 25mg is correct.
2. If it says "Dapagliflozin", then 25mg is an error—do not use.

In Pakistan,